Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases

Author(s): David S. Jones

Journal Name: Current Medicinal Chemistry

Volume 12 , Issue 16 , 2005


Become EABM
Become Reviewer
Call for Editor

Abstract:

This review covers the design and development of B cell Toleragens, compounds developed for the treatment of antibody-mediated autoimmune diseases by antigen-specific suppression of autoantibodies. Multivalent forms of B cell epitopes consisting of oligonucleotides, peptides, proteins and polysaccharides are under various stages of development for treating systemic lupus nephritis, antiphospholipid syndrome, and organ rejection associated with xenotransplantation. The design and structure of the multivalent ligands are presented along with relevant biological results. Hapten-polymer conjugates that were used to elucidate the principles of B cell suppression are included. Multivalent ligands for T cell receptors and high affinity IgE receptors, which provide insight into immunoglobulin aggregation and signaling, are also briefly discussed.

Keywords: autoantibody, self-antigen, Immunotherapy, b cell receptors (bcr), igm, b cell suppression, epitopes, oligonucleotide, xenotransplantation

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 16
Year: 2005
Published on: 01 March, 2012
Page: [1887 - 1904]
Pages: 18
DOI: 10.2174/0929867054546681
Price: $65

Article Metrics

PDF: 4